HCV cure for everyone or which challenges remain?
Following the approval of the first HCV direct-acting antiviral (DAA) in 2011, an unforeseen revolution in the treatment of chronic hepatitis C has taken place. In 2015 several all-oral DAA regimens, combining agents from different families (NS5B nucleotide inhibitors, NS5B non-nucleoside inhibitors...
保存先:
| 第一著者: | |
|---|---|
| フォーマット: | 図書 |
| 出版事項: |
Elsevier,
2015-04-01T00:00:00Z.
|
| 主題: | |
| オンライン･アクセス: | Connect to this object online. |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|
インターネット
Connect to this object online.3rd Floor Main Library
| 請求記号: |
A1234.567 |
|---|---|
| 所蔵 1 | 利用可 |